Common Contracts
10 similar Placement Agency Agreement contracts by Super League Gaming, Inc., DarioHealth Corp., Matinas BioPharma Holdings, Inc., others
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 2nd, 2023 • Super League Gaming, Inc. • Services-amusement & recreation services • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation (“Aegis” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by Super League Gaming, Inc., a Delaware corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Shares”) of Series AA Convertible Preferred Stock, par value $0.001 per share (including all subseries of such stock, the “Series AA Preferred Stock”). The Offering will consist of a minimum of 3,500 Shares ($3,500,000) (“Minimum Offering Amount”) and up to a maximum of 20,000 Shares ($20,000,000) (“Maximum Offering Amount”) which shall be offered on a “reasonable efforts, all or none” basis as to the Minimum Offering Amount and a “reasonable efforts” basis for all amounts in excess of the Minimum Offering Amount. In the event the Offering is overs
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 18th, 2023 • Super League Gaming, Inc. • Services-amusement & recreation services • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation (“Aegis” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by Super League Gaming, Inc., a Delaware corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Shares”) of Series AA Convertible Preferred Stock, par value $0.001 per share (including all subseries of such stock, the “Series AA Preferred Stock”). The Offering will consist of a minimum of 3,500 Shares ($3,500,000) (“Minimum Offering Amount”) and up to a maximum of 20,000 Shares ($20,000,000) (“Maximum Offering Amount”) which shall be offered on a “reasonable efforts, all or none” basis as to the Minimum Offering Amount and a “reasonable efforts” basis for all amounts in excess of the Minimum Offering Amount. In the event the Offering is overs
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 31st, 2023 • Super League Gaming, Inc. • Services-amusement & recreation services • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which [***] (“[***]” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by Super League Gaming, Inc., a Delaware corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Shares”) of Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”). The Offering will consist of a minimum of 5,000 Shares ($5,000,000) (“Minimum Offering Amount”) and up to a maximum of 30,000 Shares ($30,000,000) (“Maximum Offering Amount”) which shall be offered on a “reasonable efforts, all or none” basis as to the Minimum Offering Amount and a “reasonable efforts” basis for all amounts in excess of the Minimum Offering Amount. In the event the Offering is oversubscribed, the Company and Placement Agent may, in their mutual discretion, hav
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 8th, 2020 • DarioHealth Corp. • Surgical & medical instruments & apparatus • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation (“Aegis” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by DarioHealth Corp., a Delaware corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares of common stock, par value $0.0001 of the Company (“Common Stock”) issued at the “Minimum Price” (as defined in Nasdaq Rule 5635(d)) rounded down to the nearest whole share. The Company is also offering to certain purchasers, pre-funded warrants to purchase shares of Common Stock, in lieu of purchasing shares of Common Stock (the “Pre-Funded Warrants”). The purchase price of each Pre-Funded Warrant will be equal to the Minimum Price applicable for the closing in which the Pre-Funded Warrants are issued, minus $0.0001, and the exercise price of each Pre-Funded Wa
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 21st, 2020 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation (“Aegis” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Shares”) of Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”). The Offering will consist of a minimum of 10,000 Shares ($10 million) (“Minimum Offering Amount”) and up to a maximum of 20,000 Shares ($20 million) (“Maximum Offering Amount”) which shall be offered on a “reasonable efforts, all or none” basis as to the Minimum Offering Amount and a “reasonable efforts” basis for all amounts in excess of the Minimum Offering Amount. In the event the Offering is oversubscribed, the Company and Placement A
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 17th, 2020 • DarioHealth Corp. • Surgical & medical instruments & apparatus • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation (“Aegis” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by DarioHealth Corp., a Delaware corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of up to an aggregate of 20,000 shares (the “Shares”) of Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”). The Offering will consist of a minimum of 8,000 Shares ($8,000,000) (“Minimum Offering Amount”) and up to a maximum of 15,000 Shares ($15,000,000) (“Maximum Offering Amount”) which shall be offered on a “reasonable efforts, all or none” basis as to the Minimum Offering Amount and a “reasonable efforts” basis for all amounts in excess of the Minimum Offering Amount. In the event the Offering is oversubscribed, the Comp
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 2nd, 2016 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement ("Agreement") sets forth the terms upon which Aegis Capital Corp., a New York corporation, and a registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") (the “Placement Agent”), shall be engaged by Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Series A Preferred Shares”) of Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), of the Company. Each Series A Preferred Share will (i) have a dividend of 8% per annum payable in shares of Common Stock (as defined below), to be accrued until conversion, (ii) have a liquidation preference of $5.00 per Series A Preferred Share, and thereafter will participate with the Common Stock, as such term is defined below, on an as-converted basis and (iii) be convertible into 10 shares (“Shares”) of common
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 17th, 2015 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement ("Agreement") sets forth the terms upon which Aegis Capital Corp., a New York corporation, and a registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") (the “Placement Agent”), shall be engaged by Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of units (“Units”) of securities of the Company, each Unit consisting of (i) 1 share of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Shares”) and (ii) 1 warrant (the “Warrants”), with each Warrant entitling the holder to purchase one share of Common Stock for a five-year period at an exercise price of $0.75 per share. The Offering will consist of a minimum of 7,000,000 Units ($3,500,000) (the “Minimum Amount”) and a maximum of 14,000,000 Units ($7,000,000) (the “Maximum Amount”). In the event the Offering is oversubscri
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 17th, 2014 • Globeimmune Inc • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation, and a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (the “Placement Agent”), shall be engaged by GlobeImmune, Inc., a Delaware corporation (the “Company”), to act as its exclusive Placement Agent in connection with the private placement (the “Offering”) of units (“Units”) of securities of the Company, each Unit consisting of (i) a 10% Convertible Term Note in a principal amount of $250,000 (each, a “Note” and collectively, the “Notes”), convertible into securities of the Company determined as set forth in the Notes, and (ii) a warrant (each, a “Warrant” and collectively, the “Warrants”), with each Warrant entitling the holder to purchase $250,000 of securities of the Company determined as set forth in the Warrants. The Offering will consist of a maximum of 20 Units ($5,000,000) (the “Maximum Amount”). If the Offering i
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 31st, 2010 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
Manhattan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (the “Agreement”) with National Securities Corporation, a Washington corporation (the “Placement Agent”) as follows:
